[Results] Serum WFA+ – CSF1R levels were significantly higher in LC than CH patients [216.9 (34.3574.8) ng/ml vs. 82.3 (5.0-241.0) ng/ml] (p<0.001). In

LC patients without HCC (n = 77), the median WFA+ – CSF1R levels were 214.8 (34.4-479.3) ng/ml, and the WFA+/Total – CSF1R ratio was 0.21 (0.06-0.64). The AUC of WFA+ – CSF1R for predicting overall survival calculated by time-dependent ROC analysis was 0.868, and the HR was 2.20 (95% CI, 1.48-3.27, p < 0.001). The Ponatinib purchase AUC of WFA+-CSF1R for predicting survival was superior to other markers such as age, platelet count, AFP, and APRI, and was equivalent to Fib4. The survival rate of LC patients with high WFA+ – CSF1R levels (>230 ng/ml) was significantly worse than in those with lower levels

(p<0.0001), and similar data were observed in those with high albumin levels (>3.5 g/dl, n = 52). Furthermore, the AUC of WFA+/Total-CSF1R ratio for predicting the cumulative carcinogenesis rate was 0.898, with an HR of 1.36 (95% CI 1.001.85, p=0.047). The AUC of WFA+/Total-CSF1R ratio was superior Hydroxychloroquine clinical trial to other fibrosis and tumor markers (i.e. Fib4, APRI, albumin, AFP, AFP-L3 and DCP) for predicting the cumulative carcinogenesis rate. In fact, the carcinogenesis rate was significantly higher in LC patients having the high ratio of WFA+/ Total-CSF1R (>0.35, p=0.0019). The 4-year cumulative carcinogenesis rate in the group with a high WFA+/Total – CSF1R ratio was significantly higher (70% vs. 36%). [Conclusions] Assessing serum levels of WFA+-CSF1R has diagnostic utility for predicting carcinogenesis and survival of LC patients. Disclosures: Yasuhito Tanaka – Grant/Research Support: Chugai Pharmaceutical CO., LTD., MSD, Mitsubishi Tanabe Pharma Corporation, Dainippon Sumitomo Pharma Co., Ltd., DAIICHI SANKYO COMPANY, LIMITED, Bristol-Myers Squibb The following people have nothing to disclose: Etsuko Iio, Makoto Ocho, Akira Togayachi, Noboru Shinkai, Masanori Nojima, Atsushi 上海皓元医药股份有限公司 Kuno, Yuzuru Ikehara, Izumi Hasegawa, Kei Fujiwara, Shunsuke Nojiri, Takashi Joh, Masashi Mizokami, Hisashi Narimatsu Introduction: Studies suggest

that cholecystectomy is a risk factor for nonalcoholic fatty liver disease, but it is not known whether cholecystectomy is a risk factor for the progression of other chronic liver diseases such as hepatitis C virus (HCV) infection. The aim of this study is to assess whether cholecystectomy is associated with increased rates of fibrosis, increased incidence of cirrhosis and cirrhosis-related complications in patients with chronic HCV infection. Methods: Among a total of 5,236 HCV-positive patients at the VA North Texas Healthcare System, we retrospectively reviewed records of 88 patients who had undergone cholecystectomy between 1998 and 2013. We compared outcomes of these patients to 129 age, race, and gender matched HCV-positive patients without cholecystectomy, who had failed prior HCV-directed therapy.